Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.

@article{Black2007EfficacyAS,
  title={Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.},
  author={Henry R. Black and George L Bakris and Michael D Weber and Robert Jason Weiss and Mahfouz El Shahawy and Richard Marple and Georges Tannoury and Stuart L. Linas and Brian L. Wiens and Jennifer V. Linseman and Robert Roden and Michael J. Gerber},
  journal={Journal of clinical hypertension},
  year={2007},
  volume={9 10},
  pages={
          760-9
        }
}
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant hypertension, receiving background therapy with >/=3 antihypertensive medications including a diuretic at full doses, were randomized 2:1 to increasing doses of darusentan (10, 50, 100, 150, and 300 mg), a selective endothelin receptor antagonist, or matching placebo once daily for 10 weeks. Darusentan treatment decreased mean systolic and diastolic blood pressure levels in a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 citations